TickerTalks
Browse all tickers →
TickerTalks›$UCBJF
UCUCBJF

UCB S.A.

Strong FundamentalsStrong FundamentalsRevenue growing 53% YoY at strong marginsCatalyst pendingQuiet on X (1 mention/wk)
$UCBJF·$51B·Medical - Pharmaceuticals·Healthcare
$263.84-2.2%
Mentions · last 7 days
2026-07-25: 0 posts2026-07-26: 0 posts2026-07-27: 0 posts2026-07-28: 0 posts2026-07-29: 0 posts2026-07-30: 1 posts2026-07-31: 0 posts1
Price updated just now·X counts updated 3d ago
UCUCBJF
$UCBJFUCB S.A.
$263.84-2.16%1 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $UCBJF, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-08-03

The move is getting stronger, with heavier trading behind it.

UCB SA is the neurological-and-immunological biopharmaceutical franchise at 45%-of-range — Q2 EPS beat +34% plus guidance upgrade plus 52% revenue growth is the substance.

UCB S.A. (Belgium, US-listed ADR) is a specific US-listed neurological-and-immunological biopharmaceutical franchise — Cimzia (inflammatory TNF-mediated diseases), Bimzelx (psoriasis/PsA/AS), Rystiggo, Zilbrysq, plus epilepsy franchise. Flat today, YTD n/a (ADR history), t12m n/a, sitting at the 45th percentile of the 52-week range on a Q2-beat-plus-guidance-upgrade tape.

Where it stands after Q2:

  • The Q2 print was a specific beat: EPS $7.81 vs $5.81 estimate (+34%) plus revenue $4.88B vs $4.64B — Multi-quarter revenue at $3.36B-$4.88B with 30-60% YoY growth, gross margin 73-77%, operating margin 19-33%, and EPS $4.51, $2.50, $5.69, $5.82.
  • The valuation is undemanding: TTM P/E of 19, forward P/E on FY26 EPS estimates of $10.85 rising to FY27 $13.46 and FY28 $16.57 (n=1 EPS analyst, n=14-16 on revenue). Price-to-sales of 5.0, EV/EBITDA of 21.0, ROE 19.5%, ROIC 14.1%, and 4.6% FCF yield describe a specific quality-plus-growth setup on the $51B market cap.
  • The 4-quarter earnings-surprise cadence is mostly constructive: EPS $7.81 vs $5.81 (+34%), $7.59 vs $5.83 (+30%), $2.88 vs $3.89 (-26%), $4.56 vs $2.68 (+70%) — Q2 2025 miss was the exception.
  • The counterweight is specific: UCB shares fall despite guidance upgrade as investors question earnings quality (Reuters 7/30) — a real specific risk framing.

Feb 25 2027 FY26 earnings needs continued Cimzia-plus-Bimzelx revenue growth plus dated commentary on the FY26 guidance-upgrade execution and cash-flow-plus-earnings-quality trajectory to extend the accelerating tape; a specific earnings-quality walk-back or a customer-plus-competitive disclosure would take the stock back toward the 200-day base.

What to watch: Feb 25 2027 FY26 earnings — good = continued Cimzia-plus-Bimzelx revenue growth with dated commentary on the FY26 guidance-upgrade execution and cash-flow-plus-earnings-quality trajectory; bad = a specific earnings-quality walk-back or a customer-plus-competitive disclosure, which takes the stock back toward the 200-day base.

On the calendar: 2027-02-25 — FY26 earnings

Read the AI verdict + X sentiment for $UCBJF

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

UCB S.A. is a prominent biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for individuals affected by neurological and immunological disorders. Its extensive portfolio of marketed products includes Cimzia, indicated for various inflammatory TNF-mediated diseases such as Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and axial spondyloarthritis (both radiographic and non-radiographic forms). For epilepsy management, UCB provides Vimpat, Keppra, and Briviact, alongside Nayzilam, a specialized nasal spray for acute rescue treatment of seizure clusters. Neupro is available for patients with Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Additionally, the company offers Evenity to treat osteoporosis in postmenopausal women, and BIMZELX, approved for conditions like psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also part of its offerings for systemic lupus erythematosus. In its robust development pipeline, UCB is advancing several investigational medicines, including rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged stereotypical seizures; Bepranemab targeting Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its core pharmaceutical activities, UCB also provides contract manufacturing services. The company has forged strategic collaboration agreements with major industry players such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. With its headquarters in Brussels, Belgium, and established in 1925, UCB maintains a significant international presence, operating across the United States, Japan, Germany, China, Belgium, and other key European markets including France, Italy, Spain, the United Kingdom, and Ireland.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Pharmaceuticals sits in its cycle right now — and what that implies for $UCBJF.

Medical - Pharmaceuticals · Healthcare

No material change from last week — Trump's executive order support and DEA rescheduling progress create a viable regulatory pathway while ATAI's pipeline advances toward multiple late-stage data..

Industry benchmark

5-name peer basket
+77.7%YTD
+79.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
19.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
14.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
31.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
19.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
76.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$7.81$5.81+34.4%
Q4 2025Feb 26, 2026$7.59$5.83+30.2%
Q2 2025Jul 31, 2025$2.88$3.89-26.0%
Q4 2024Feb 27, 2025$4.56$2.68+70.1%
Next earningsThu, Feb 25·consensus EPS $6.27

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$4.3B+52.8%74.6%33.3%$5.82$82.9M
Q4 FY25$4.3B+59.7%74.9%30.3%$5.69$1.4B
Q2 FY25$3.5B+34.7%73.6%19.2%$2.50$593.0M
Q4 FY24$3.4B+29.7%73.2%29.8%$4.51$659.0M

Forward consensus

5-year forecast · up to 16 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$8.4B$8.1B – $8.8B$10.85$10.13 – $11.9816
FY27$9.5B$8.9B – $10.5B$13.46$12.57 – $14.8616
FY28$10.6B$10.1B – $11.4B$16.57$15.48 – $18.3014
FY29$11.7B$11.1B – $12.7B$20.40$19.06 – $22.5315
FY30$12.6B$12.0B – $13.6B$23.40$21.87 – $25.8515

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.45%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-7.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-8.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 117.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.205-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.ListedOTCListed on an over-the-counter market (PNK / OTCQB / OTCQX), not a major exchange. Lower disclosure requirements and thinner liquidity.

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

UCB SA (UCBJY) Q2 2026 Earnings Call Transcriptseekingalpha.com·3d agoUCB shares fall despite guidance upgrade as investors question earnings qualityreuters.com·5d agoUnited Community Banks, Inc. (UCB) Q2 2026 Earnings Call Transcriptseekingalpha.com·13d agoUnited Community Banks (UCB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimateszacks.com·13d agoUnited Community Banks (UCB) Q2 Earnings and Revenues Miss Estimateszacks.com·13d ago

More in Medical - Pharmaceuticals

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LQDA$PAVS$CORT$KNSA$CIRC$SGIPF
Voices on X · last 7 days

No standout posts about $UCBJF on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport